- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00672633
Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides
A Double Blind Randomized Controlled Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators propose to conduct a placebo controlled, double blind, parallel group randomized trial to evaluate the efficacy of Lovaza (formerly known as Omacor) in reducing triglyceride levels in youth ages 10-19 years old whose baseline triglycerides range from150 mg/dl to 1000 mg/dl. Seventy subjects will be recruited at baseline and randomized to the treatment condition, Lovaza 4 grams/day for 6 months or the control condition, a corn oil placebo, 4 tablets a day for 6 months. Participants in both the treatment and control groups will receive the standard of care, which is dietary advice to follow a low, refined carbohydrate and low saturated fat diet that emphasizes increasing intake of fruits and vegetables and eating 2 servings per week of fishes rich in omega-3 fatty acids, consistent with the American Heart Association recommendations (Kris-Etherton, 2003). Subjects will be randomized to the treatment or control condition after a 4 week run-in period of dietary education and advice. The primary outcome will be change in fasting triglycerides from baseline to 3 months.
2.0 SPECIFIC AIMS
2.1 Primary Aim/Outcome
- To determine the efficacy of LOVAZA in reducing plasma triglyceride levels among adolescents, ages 12-19 years with mild to moderate hypertriglyceridemia. We hypothesize that patients who receive LOVAZA will have significantly greater reductions in plasma triglyceride levels when compared to patients on placebo at 3 months.
2.2 Secondary Aims/Outcome
- To determine whether the efficacy of LOVAZA varies with duration of treatment, 3 months versus 6 months.
- To determine the effects of LOVAZA on plasma HDL and LDL cholesterol at 3 months and 6 months.
- To determine the effects of LOVAZA on systolic and diastolic blood pressure at 3 months and 6 months.
2.3 Exploratory Aims
- To describe the effects of LOVAZA on vascular reactivity/endothelial function as measured by pulse amplitude at 3 months and 6 months.
- To describe the effects of LOVAZA on levels of biomarkers of inflammation as measured by C-Reactive Protein at 3 months and 6 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages 10-19 years old
- Fasting Triglyceride levels of 150-1000 mg/dl at the screening and baseline visit
- Ability to swallow pills
- Informed consent from a parent or legal guardian of minors or adult subject
- Written assent from the adolescent to participate in the study
- English or Spanish speaking
Exclusion Criteria:
- Food Allergy to Fish or any components of the pills which includes alpha tocopherol, partially hydrogenated vegetable oils including soybean oils and gelatin and glycerol or corn oil, and iron oxide or iron oxide containing food color additives.
- Pregnancy or positive urine pregnancy test for those females who have begun menstruating
- Breast feeding
- Alcohol Use: Patient is unable to abstain from alcohol use during the study. This will be assessed by asking the following questions: "During the past 30 days, on how many days did you have at least one drink of alcohol?"; "During the past 30 days, on how many days did you have 5 or more drinks of alcohol in a row, that is, within a couple of hours?"; "This study requires that you abstain from alcohol use during the course of the study. Do you think you can do this?"
- Known Bleeding Disorder or Coagulopathy or treatment with anticoagulant medications or low platelet counts, abnormal PT, or PTT.
- Significant cognitive or psychosocial disorder or medical illness that would limit participation in the trial.
- Type 1 or 2 Diabetes or fasting glucose that is >=126 mg/dl
- Liver disease or an ALT greater than 2 times upper limit of normal
- Treatment with medications that affect triglyceride levels, including oral hypoglycemic agents or insulin.
- Be currently taking the same oral contraceptive pills for less than the past three months or intend to change or discontinue prescription oral contraceptive pills used in the next seven months
- Be currently taking any over-the-counter supplements that affect triglycerides or lipid metabolism including over the counter fish oil supplements.
- Treatment for or diagnosis of a thyroid disorder or an elevated TSH level at baseline
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A , Experimental
Lovaza, 4 grams/day orally for 6 months
|
Lovaza , 4 grams/day orally for 6 months
|
Placebo Comparator: Corn Oil Pill
Corn Oil Pill, 4 pills/day orally for 6 months
|
Corn Oil Pill, 4 pills/day orally for 6 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting Triglycerides
Time Frame: 3 months
|
Fasting Triglycerides
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL Cholesterol
Time Frame: 3 months
|
Low Density Lipoprotein Cholesterol
|
3 months
|
HDL Cholesterol
Time Frame: 3 months
|
High Density Lipoprotein Cholesterol
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stavroula K Osganian, MD, ScD, Boston Children's Hospital
- Principal Investigator: Sara DeFerranti, MD, Boston Children's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08010028
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertriglyceridemia
-
Arrowhead PharmaceuticalsRecruitingSevere HypertriglyceridemiaUnited States
-
89bio, Inc.RecruitingSevere HypertriglyceridemiaUnited States, Bulgaria, Canada, Latvia, Spain, Austria, Belgium, Czechia, Georgia, Hungary, Poland, Puerto Rico, Argentina, Chile, France, Germany, United Kingdom, India, Italy
-
Ionis Pharmaceuticals, Inc.Active, not recruitingSevere HypertriglyceridemiaFinland, United States, France, Israel, Netherlands, Denmark, Spain, Australia, United Kingdom, Germany, Italy, Canada, Czechia, Turkey, Hungary, Bulgaria, New Zealand, Sweden, South Africa, Poland, Norway, Portugal, Slovakia
-
Sancilio and Company, Inc.WithdrawnSevere Hypertriglyceridemia
-
Arrowhead PharmaceuticalsCompletedSevere HypertriglyceridemiaUnited States, Netherlands, Australia, Canada, New Zealand, Poland, Hungary, Germany
-
AstraZenecaCompletedSevere HypertriglyceridemiaUnited States, Hungary, India, Russian Federation, Denmark, Ukraine, Netherlands
-
AstraZenecaRadiant ResearchCompletedSevere HypertriglyceridemiaUnited States
-
Trygg Pharma, Inc.UnknownSevere HypertriglyceridemiaUnited States
-
National Taiwan University HospitalUnknownHypertriglyceridemia During PregnancyTaiwan
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
Clinical Trials on Lovaza
-
University of VirginiaReliant PharmaceuticalsWithdrawn
-
AstraZenecaCompletedSevere HypertriglyceridemiaUnited States, Canada
-
University of MichiganGlaxoSmithKlineTerminated
-
St. Luke's-Roosevelt Hospital CenterGlaxoSmithKlineNo longer available
-
University of TennesseeUnknownParenteral Nutrition Associated Liver DiseaseUnited States
-
University of UtahGlaxoSmithKlineWithdrawnEffects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in HypertriglyceridemiaHypertriglyceridemiaUnited States
-
University of Illinois at ChicagoTerminatedNonalcoholic Steatohepatitis (NASH) | Hepatic SteatosisUnited States
-
Milton S. Hershey Medical CenterWithdrawn
-
Brigham and Women's HospitalGlaxoSmithKlineUnknown
-
United States Department of DefenseGlaxoSmithKlineUnknownDepression | Mood Disorders | Combat Disorders | Stress DisordersIraq